Literature DB >> 24287764

Drugging cancer genomes.

Paul Workman1, Bissan Al-Lazikani.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24287764     DOI: 10.1038/nrd4184

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

Review 1.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

Review 2.  A census of human cancer genes.

Authors:  P Andrew Futreal; Lachlan Coin; Mhairi Marshall; Thomas Down; Timothy Hubbard; Richard Wooster; Nazneen Rahman; Michael R Stratton
Journal:  Nat Rev Cancer       Date:  2004-03       Impact factor: 60.716

Review 3.  Objective assessment of cancer genes for drug discovery.

Authors:  Mishal N Patel; Mark D Halling-Brown; Joseph E Tym; Paul Workman; Bissan Al-Lazikani
Journal:  Nat Rev Drug Discov       Date:  2013-01       Impact factor: 84.694

4.  canSAR: an integrated cancer public translational research and drug discovery resource.

Authors:  Mark D Halling-Brown; Krishna C Bulusu; Mishal Patel; Joe E Tym; Bissan Al-Lazikani
Journal:  Nucleic Acids Res       Date:  2011-10-19       Impact factor: 16.971

5.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

  5 in total
  21 in total

Review 1.  Ten things you should know about protein kinases: IUPHAR Review 14.

Authors:  Doriano Fabbro; Sandra W Cowan-Jacob; Henrik Moebitz
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

2.  EMBO conference series: Chemical Biology 2014.

Authors:  Eileen J Kennedy
Journal:  Chembiochem       Date:  2014-10-16       Impact factor: 3.164

3.  EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.

Authors:  Michel Wassef; Armelle Luscan; Setareh Aflaki; Dina Zielinski; Pascal W T C Jansen; H Irem Baymaz; Aude Battistella; Carole Kersouani; Nicolas Servant; Margaret R Wallace; Pierre Romero; Olivier Kosmider; Pierre-Alexandre Just; Mikaël Hivelin; Sébastien Jacques; Anne Vincent-Salomon; Michiel Vermeulen; Michel Vidaud; Eric Pasmant; Raphaël Margueron
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-13       Impact factor: 11.205

Review 4.  Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.

Authors:  V Mouraviev; B Lee; V Patel; D Albala; T E B Johansen; A Partin; A Ross; R J Perera
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-10-27       Impact factor: 5.554

5.  Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Authors:  David C Wedge; Gunes Gundem; Thomas Mitchell; Dan J Woodcock; Inigo Martincorena; Mohammed Ghori; Jorge Zamora; Adam Butler; Hayley Whitaker; Zsofia Kote-Jarai; Ludmil B Alexandrov; Peter Van Loo; Charlie E Massie; Stefan Dentro; Anne Y Warren; Clare Verrill; Dan M Berney; Nening Dennis; Sue Merson; Steve Hawkins; William Howat; Yong-Jie Lu; Adam Lambert; Jonathan Kay; Barbara Kremeyer; Katalin Karaszi; Hayley Luxton; Niedzica Camacho; Luke Marsden; Sandra Edwards; Lucy Matthews; Valeria Bo; Daniel Leongamornlert; Stuart McLaren; Anthony Ng; Yongwei Yu; Hongwei Zhang; Tokhir Dadaev; Sarah Thomas; Douglas F Easton; Mahbubl Ahmed; Elizabeth Bancroft; Cyril Fisher; Naomi Livni; David Nicol; Simon Tavaré; Pelvender Gill; Christopher Greenman; Vincent Khoo; Nicholas Van As; Pardeep Kumar; Christopher Ogden; Declan Cahill; Alan Thompson; Erik Mayer; Edward Rowe; Tim Dudderidge; Vincent Gnanapragasam; Nimish C Shah; Keiran Raine; David Jones; Andrew Menzies; Lucy Stebbings; Jon Teague; Steven Hazell; Cathy Corbishley; Johann de Bono; Gerhardt Attard; William Isaacs; Tapio Visakorpi; Michael Fraser; Paul C Boutros; Robert G Bristow; Paul Workman; Chris Sander; Freddie C Hamdy; Andrew Futreal; Ultan McDermott; Bissan Al-Lazikani; Andrew G Lynch; G Steven Bova; Christopher S Foster; Daniel S Brewer; David E Neal; Colin S Cooper; Rosalind A Eeles
Journal:  Nat Genet       Date:  2018-04-16       Impact factor: 38.330

Review 6.  Chromatin Remodelers: From Function to Dysfunction.

Authors:  Gernot Längst; Laura Manelyte
Journal:  Genes (Basel)       Date:  2015-06-12       Impact factor: 4.096

Review 7.  TP53: an oncogene in disguise.

Authors:  T Soussi; K G Wiman
Journal:  Cell Death Differ       Date:  2015-05-29       Impact factor: 15.828

Review 8.  Leaving the lysosome behind: novel developments in autophagy inhibition.

Authors:  Abigail R Solitro; Jeffrey P MacKeigan
Journal:  Future Med Chem       Date:  2015-12-21       Impact factor: 3.808

Review 9.  A comprehensive map of molecular drug targets.

Authors:  Rita Santos; Oleg Ursu; Anna Gaulton; A Patrícia Bento; Ramesh S Donadi; Cristian G Bologa; Anneli Karlsson; Bissan Al-Lazikani; Anne Hersey; Tudor I Oprea; John P Overington
Journal:  Nat Rev Drug Discov       Date:  2016-12-02       Impact factor: 84.694

10.  A global assessment of cancer genomic alterations in epigenetic mechanisms.

Authors:  Muhammad A Shah; Emily L Denton; Cheryl H Arrowsmith; Mathieu Lupien; Matthieu Schapira
Journal:  Epigenetics Chromatin       Date:  2014-12-04       Impact factor: 4.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.